Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,419.98 -384.34 (-0.60%) CMC Crypto 200
1,332.88 -63.65 (-4.56%)
Gyre Therapeutics, Inc. (GYRE)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 16.33 |
| Open | 16.33 |
| Bid | 16.96 x 100 |
| Ask | 17.13 x 200 |
| Day's range | 15.90 - 17.25 |
| 52-week range | 3.00 - 30.40 |
| Volume | |
| Avg. volume | 79,493 |
| Market cap | 1.526B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more...
- GuruFocus.com
Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress
Transformational Year with Strategic Shifts and Clinical Advances
GlobeNewswireGyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Data readout from Phase 3 clinical trial in the People's Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreeme
© 2024 Yahoo. All rights reserved.